



899 NORTH CAPITOL ST. NE – 2ND FLR. WASHINGTON, DC 20002

October 6, 2022

9:30 am

OPEN SESSION AGENDA (VIA WEBEX MEETING)

Board of Pharmacy Mission Statement:

"To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians."

CALL TO ORDER:	

PRESIDING:

BOARD MEMBERSHIP/ATTENDANCE:

	•	
BOARD MEMBERS:		
	DR. TAMARA MCCANTS, PHARM.D. R.PH CHAIRPERSON	
	Mr. Alan Friedman, R.PH, Vice Chairperson	
	Dr. Benjamin MILES, PHARM.D. R.PH	
	Dr. Ashlee Bow, Pharm.D. R.PH	
	Dr. Allison Hill, Pharm.D. R.PH	
STAFF:	DR. JUSTIN ORTIQUE, EXECUTIVE DIRECTOR	
	KARIN BARRON, HEALTH LICENSING SPECIALIST	
	LUANNE GREENAWAY, PROGRAM SPECIALIST	
	COUNTEE GILLIAM, BOARD INVESTIGATOR	
LEGAL STAFF:	CARLA WILLIAMS, SENIOR ASSISTANT GENERAL COUNSEL	
LLUAL STAIT.	CARLA WILLIAMS, SENIOR ASSISTANT GENERAL COUNSEL	
VISITORS:		
VISITORS.		
		ı

Open Session Agenda

Quorum:

Introduction:		
1006-O-01	Approval of the Open Session Meeting Minutes for: August 4, 2022 September 1, 2022	
Consent Agenda	None	
<u>Chairperson</u> <u>Report</u>	Interprofessional Workgroup	Dr. Tamara McCants
Executive Director Report	 Statistical Report on Pharmacy professionals in the District of Columbia Prescription Drug Monitoring Program Updates DCRx (DC Center for Rational Prescribing) Office of Government Relations (OGR) Updates 	Dr. Justin Ortique
Senior Assistant General Counsel Report		
1006-0-02	Notice of Proposed Rulemaking-Published in the D.C. Register for Public Comment (a) Proposed Rulemaking for Chapter 65 for Pharmacists	Ms. Carla Williams
Regarding Subcommittee Reports		
1006-O-03	Legislative and Regulatory Subcommittee Report	Mr. Alan Friedman
1006-O-04	Communications Subcommittee Report	Dr. Ashlee Bow
Presentation	Fall campaign for COVID & Flu and Update on Vaccine Administration Reporting Requirements	Ms. Heather Burris, Immunization Division Chief
NABP E- Newsletter	September 21, 2022 FDA Releases Framework Aimed to Prevent Drug Overdoses and Reduce Deaths	Dr. Tamara McCants

	Impact of Laws on Pediatric Opioid Prescribing
	How Pharmacists Can Address Vaccine Hesitancy for the Flu and Beyond
	FDA's Self-Guided Online Course: Personnel Gowning in Sterile Drug Production
	FDA Asks Boards to Report Concerns on Unlicensed Desiccated Thyroid Extract
	Importation of Prescription Drugs: Overview of the Final Rule, FDA Guidance, and Obstacles to Implementation
	September 14, 2022
	Study: Increased Use of Telehealth Services for OUD During Pandemic Cuts Overdose Risk
	FDA Webinar on Preventive Vaccines
	DEA Warns of Brightly Colored Fentanyl Used to Target Young Americans
	During Pandemic, Nearly One in Four Youth Sought Mental Health Care
	Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/ .
Comments from the Public	
Motion to Adjourn the Open Session	"Madam Board Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." ROLL CALL VOTE

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code \S 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at _:_ AM.

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.